Patients with advanced sensitive non-T790M EGFR-mutant NSCLC resistant to first/second-generation EGFR-TKI reported moderate activity and good toxicity tolerance when EGFR-TKI was re-administered with afatinib [62]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.